STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.